AAN 2026 | Semaglutide and the risk of adult-onset epilepsy in type 2 diabetes

Hyunyong Howard Koh, MD, PhD, Baylor College of Medicine, Houston, TX, discusses a target trial emulation and mediation analysis exploring semaglutide and the risk of adult-onset epilepsy in type 2 diabetes. Dr Koh highlights that the study found a protective effect of semaglutide on the occurrence of late-onset seizures in adults compared with other glucose-lowering agents. This interview took place at the 78th American Academy of Neurology (AAN) Annual Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.